Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

FLEBOGAMMA DIF Solution for infusion (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Flebogamma DIF 50 mg/ml solution for infusion.

Qualitative and quantitative composition

Human normal immunoglobulin (IVIg). <u>One ml contains:</u> Human normal immunoglobulin 50 mg (purity of at least 97% of IgG). Each vial of 10 ml contains: 0.5 g of human normal immunoglobulin. Each vial ...

Pharmaceutical form

Solution for infusion. The solution is clear or slightly opalescent and colourless or pale yellow. Flebogamma DIF is isotonic, with an osmolality from 240 to 370 mOsm/kg.

Therapeutic indications

Replacement therapy in adults, children and adolescents (2-18 years) in: Primary immunodeficiency syndromes (PID) with impaired antibody production. Secondary immunodeficiencies (SID) in patients who suffer ...

Posology and method of administration

Replacement therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency. Posology The dose and dose regimen is dependent on the indication. ...

Contraindications

Hypersensitivity to the active substance (human immunoglobulins) or to any of the excipients (see sections 4.4 and 6.1). Fructose intolerance (see section 4.4). In babies and young children (aged 0-2 years) ...

Special warnings and precautions for use

Sorbitol Each ml of this medicinal product contains 50 mg of sorbitol. Patients with rare hereditary problems of fructose intolerance must not take this medicine. In persons more than 2 years old with ...

Interaction with other medicinal products and other forms of interaction

Live attenuated virus vaccines Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps ...

Fertility, pregnancy and lactation

Pregnancy The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding ...

Effects on ability to drive and use machines

The ability to drive and operate machines may be impaired by some adverse reactions, such as dizziness, associated with Flebogamma DIF. Patients who experience adverse reactions during treatment should ...

Undesirable effects

Summary of the safety profile Adverse reactions caused by human normal immunoglobulins (in decreasing frequency) encompass (see also section 4.4): chills, headache, dizziness, fever, vomiting, allergic ...

Overdose

Overdose may lead to fluid overload and hyperviscosity, particularly in patients at risk, including elderly patients or patients with cardiac or renal impairment (see section 4.4). Paediatric population ...

Pharmacodynamic properties

Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration ATC code: J06BA02 Human normal immunoglobulin contains mainly immunoglobulin ...

Pharmacokinetic properties

Human normal immunoglobulin is immediately and completely bioavailable in the recipients circulation after intravenous administration. It is distributed relatively rapidly between plasma and extravascular ...

Preclinical safety data

Single dose toxicity studies were carried out in rats and mice. The absence of mortality in the non-clinical studies performed with Flebogamma DIF with doses up to 2500 mg/kg, and the lack of any confirmed ...

List of excipients

D-sorbitol Water for injections

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products, nor with any other IVIg products.

Shelf life

2 years.

Special precautions for storage

Do not store above 30°C. Do not freeze.

Nature and contents of container

10 ml, 50 ml, 100 ml, 200 ml or 400 ml solution in a vial (type II glass) with stopper (chloro-butyl-rubber). Pack size: 1 vial Not all pack sizes may be marketed.

Special precautions for disposal and other handling

The product should be brought to room or body temperature before use. The solution should be clear or slightly opalescent and colourless or pale yellow. Solutions that are cloudy or have deposits should ...

Marketing authorization holder

Instituto Grifols, S.A., Can Guasc, 2 Parets del Vallès, 08150, Barcelona Spain

Marketing authorization number(s)

EU/1/07/404/001-005

Date of first authorization / renewal of the authorization

Date of first authorisation: 23 August 2007 Date of latest renewal: 24 April 2017

Date of revision of the text

07/2019

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: